<DOC>
	<DOCNO>NCT02529059</DOCNO>
	<brief_summary>This study aim investigate whether substitution Efavirenz ( EFV ) Tenofovir/Emtricitabine/Efavirenz ( TDF/FTC/EFV ) fixed-dose combination ( FDC ) Atripla , Rilpivirine tenofovir/emtricitabine/rilpivirine ( TDF/FTC/RPV ) fixed-dose combination ( FDC ) Eviplera , lead resolution covert Central Nervous System ( CNS ) toxicity associate EFV , continue virological suppression immunological reconstitution whether associate improvement quality life , sleep , anxiety/depression neurocognitive function ; impact switch adherence also investigate .</brief_summary>
	<brief_title>SSAT058 : Atripla Eviplera Switch Patients Without Central Nervous System Symptoms</brief_title>
	<detailed_description>Protocol Summary Study Title : SSAT 058 - A phase IV , open-label , multi centre pilot study assess prevalence objective neurocognitive abnormality patient without perceived Central Nervous System ( CNS ) symptoms tenofovir/emtricitabine/efavirenz Atripla® effect switch fix dose combination tenofovir/emtricitabine/rilpivirine ( Eviplera® ) . Proposed Sponsor : St Stephen 's AIDS Trust Chief Investigator : Dr Mark Nelson Name Investigational Product : Eviplera® Name Active Ingredients : Rilpivirine , tenofovir , emtricitabine Name Non Investigational Medicinal Product : NA Name Active Ingredients : NA Phase Study : Phase IV Objectives : The objective study : Primary objective - To describe prevalence pattern , patient without self-perceived CNS symptom related tenofovir/emtricitabine/efavirenz , follow parameter assess baseline : - Objective neurocognitive function test . - Self-reported central nervous system symptom questionnaire - Reported Sleep quality Secondary objectives - change measure neurocognitive parameter baseline week 4 24 - change sleep score baseline week 4 24 - change symptom related CNS toxicity baseline 24 week - change magnetic resonance imaging ( MRI ) spectroscopy brain baseline week 24 . - rate maintain virological suppression &lt; 50 copies/ml visit 24 week - change fast lipid baseline 24 week - change report adherence baseline week 24 : - adherence - Quality life - Reported anxiety depression Study Design : Multi-centre , open-label , single pilot study 24 week . Study visit take place screening , baseline ( within 36 day screen visit ) , week 4 , 12 24 . Substudy 10 volunteer - MRI scan baseline week 24 Indication : HIV-1-infection Methodology : - Neurocognitive function test measure computerised task . - CNS symptom sleep quality determine questionnaire . - Changes CNS metabolites 1H-MR spectroscopy imaging . Planned Sample Size : 40 ( across 4 centre ) Summary Eligibility Criteria : HIV-infected individual Atripla viral load &lt; 50 copies/mL CD4 count &gt; 50 cells/mm3 . Number Study Centres : 4 Duration Treatment : 24 week Dose Route Administration : A single-pill fix dose combination tenofovir 245mg , emtricitabine 200mg rilpivirine 25mg daily . Primary Endpoint : Summary overall prevalence categorise description follow measure determine baseline : - Neurocognitive function score calculate composite score individual domain . - Reported CNS symptom assess use questionnaire base Summary Product Characteristics ( SPC ) score severity report individual composite score . - Sleep Quality assess questionnaire baseline . Secondary Endpoint : - change measure neurocognitive parameter baseline week 4 24 - change sleep score baseline week 4 24 - change symptom related CNS toxicity baseline 24 week - Change magnetic resonance image spectroscopy brain baseline week 24 . - rate maintain virological suppression &lt; 50 copies/ml visit 24 week - change fast lipid baseline 24 week - change report adherence baseline week 24 : - adherence - Quality life - Reported anxiety depression</detailed_description>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Patient volunteer meet follow criterion eligible trial : 1 . Is male female age 18 year 2 . Has HIV1 infection document medical note 3 . Has sign Informed Consent Form voluntarily 4 . Is willing comply protocol requirement 5 . Has Atripla least 12 week enrolment 6 . Has undetectable HIVplasma viral load screen local assay ( single retest allow ) 7 . Has CD4 cell count screen &gt; 50 cells/mm3 8 . Has estimate glomerular filtration rate ( MDRD ) &gt; 50 ml/min . 9 . Has significant CNS symptom may attributable EFV . 10 . If female childbearing potential , use effective birth control method ( example , hormonal contraceptive , condom , abstinence , IUD , agree investigator ) willing continue practise birth control method trial least 30 day end trial . Note : Women postmenopausal least 2 year , woman total hysterectomy , woman tubal ligation consider nonchildbearing potential 11 . If heterosexually active male , use effective birth control method willing continue practise birth control method trial followup visit Patients meet 1 follow criterion select : 1 . Infected HIV2 2 . Using concomitant therapy disallow per SPC study drug ( e.g proton pump inhibitor ) 3 . Has acute viral hepatitis include , limited , A , B , C 4 . Has chronic hepatitis B and/or C AST and/or ALT &gt; 5 x ULN Note : Patients enter trial chronic HBV HBVDNA undetectable screen ( detectable result last 6 month ) chronic HCV expect require treatment trial period . 5 . Any investigational drug within 30 day prior trial drug administration 6 . Has ever receive rilpivirine past 7 . Any clinical evidence baseline resistance mutation , prior commence antiretroviral therapy . 8 . Known allergy lactose monohydrate , sunset yellow aluminium lake ( E110 ) , patient galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption 9 . Severe hepatic impairment ( define ChildPughTurcotte ( CPT ) Score C ) . 10 . If female , pregnant breastfeed 11 . Screening blood result grade 3/4 toxicity accord Division AIDS ( DAIDS ) grade scale , except : asymptomatic grade 3 glucose , amylase lipid elevation asymptomatic grade 4 triglyceride elevation ( retest allow ) . 12 . Any condition ( include drug/alcohol abuse ) laboratory result , investigator 's opinion , interfere assessment completion trial . 13 . If participate MR Imaging substudy , contraindication magnetic resonance scan accord local radiology guideline ( assessed MR Spectroscopy Imaging Department )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>